Table 2.

Adjusted hazard ratios for unfavourable outcome, failure/relapse, and death throughout observation, stratified by HIV status where proportionality assumption is unmet. All 1006 patients, strata for missing values not displayed.

Characteristic	HIV negative		HIV positive		Total
	Ahrd	95% ci	ahrd	95% ci	ahrd	95% ci
Unfavourable outcomea
BMI < 18.5	1.6	(1.1–2.3)	2.9	(1.6–5.5)	1.8e	(1.4–2.5)
FLQ resistance	2.6	(1.4–5.1)	1.8	(0·44–7·8)	2.3e	(1.3–4.2)
INH resistance	1.7	(0.82–3.5)	2.4	(0·84–6·6)	1.9e	(1.02–3.4)
Failure/relapseb
BMI < 18.5					2.0	(1.2–3.2)
FLQ resistance					6.8	(3.5–13.2)
INH resistance					9.4	(1.3–68.0)
SLID resistance					0.27	(0.04–2.0)
Deathc
BMI < 18.5	1.6	(1.03–2.6)	2.2	(1.3–3.8)	1·7e	(1.2–2.5)
Lung lesions ≥50%	2.5	(1.4–4.5)	1.07	(0.60–1·9)	1·6e	(1.06–2.3)
SLID resistance	6.1	(2.4–15.8)	1.7	(0.23–12.6)	3·6e	(1.6–8.3)

BMI: body mass index (in kg/m²); FLQ: fluoroquinolone; INH: isoniazid; SLID: second-line injectable drug; CI: confidence interval.

^aUnfavourable outcome (death during treatment, lost to follow-up during treatment, failure during treatment, or relapse) vs relapse-free success among all 1006 patients. Not shown are the strata with missing information for the respective variable.

^bFailure during treatment or relapse during follow-up. Death throughout observation, and lost to follow-up throughout observation are censored. Not shown are the strata with missing information for the respective variable.

^cDeath throughout observation. Failure during treatment, relapse, and lost to follow-up throughout observation are censored Not shown are the strata with missing information for the respective variable.

^daHR: adjusted hazard ratio calculated from a Cox proportional hazard model using variables after stepwise elimination. Adjusted refers to the listed other variables for each characteristic.

^eThe calculation of hazard ratios on the total is calculated by excluding HIV from the model as it violates the assumption of proportionality.